Long-term prognosis of patients with myocarditis attributed to COVID-19 mRNA vaccination, SARS-CoV-2 infection, or conventional etiologies
JAMA
Published 2024-08-26 · Original archive entry · Explore research explainers
About The Study: Patients with post–COVID-19 mRNA vaccination myocarditis, contrary to those with post–COVID-19 myocarditis, show a lower frequency of cardiovascular complications than those with conventional myocarditis at 18 months. However, affected patients, mainly healthy young men, may require medical management up to several months after hospital discharge.
Corresponding Authors: To contact the corresponding authors, email Laura Semenzato, MSc (laura.semenzato@assurance-maladie.fr) and Mahmoud Zureik, MD, PhD (Mahmoud.ZUREIK@ansm.sante.fr).
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.16380)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the 2024 International Society for Pharmacoepidemiology Annual Meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.16380?guestAccessKey=07ee8e37-54d7-4436-8659-20e806e46c32&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082624
END
Corresponding Authors: To contact the corresponding authors, email Laura Semenzato, MSc (laura.semenzato@assurance-maladie.fr) and Mahmoud Zureik, MD, PhD (Mahmoud.ZUREIK@ansm.sante.fr).
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.16380)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the 2024 International Society for Pharmacoepidemiology Annual Meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.16380?guestAccessKey=07ee8e37-54d7-4436-8659-20e806e46c32&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082624
END